VNTA Ventana Global Inc (PK)

Ventana Biotech Inc. ("Ventana") (PINK SHEETS: VNTA), a biotechnology company developing an appetite-suppressing chewing gum, today revealed its latest groundbreaking research in tackling yet another of the modern lifestyle-induced illnesses: Stress!

Ventana Biotech Inc. is proud to reveal that it is conducting research in developing a Stress Suppressing Chewing Gum that builds on its experience with its current line of anti-obesity products. Having gained experience with stimulating the body's own natural hormones in suppressing appetite, Ventana has commenced similar research with the aim of suppressing stress.

A preliminary estimate of the royalty cash-flow from a successful stress-suppressing drug is at USD 1.6 - 1.9 billion over a 10 year period.

Stress kills and disables millions of people in the world, where the pressure for constantly adjusting to an ever-increasing plethora of demands simply knocks people off their feet. Prolonged stress leads to a disabling and chronic condition: Post-Traumatic Stress Syndrome (PTSS). Until about ten years ago, this used to only affect soldiers, paramedics and a few others who had to work under unbearable circumstances, but recently the ratio of "ordinary office workers" getting PTSS has increased at an alarming rate, leading to millions of people suffering from PTSS today!

Having PTSS is a life-debilitating illness, in effect causing the victims to be unable to handle everyday living, including having even the simplest job, shopping, cooking, travelling, and co-existing with children or others. And most distressing, there is no cure in the ordinary sense. Once a person has been stressed beyond the breaking-point, there is almost never any chance of getting back to a normal life with a job and family. It is therefore of utmost importance to make sure never to cross that invisible boundary between "healthy stress" and crippling stress. Ventana's new Stress Suppressing Chewing Gum will do just that, and prevent people from getting stressed beyond the breaking point.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

For more information about Ventana Biotech Inc please contact investor@ventanabiotech.com.

Contacts: Ventana Biotech Inc Janne Christensen CEO +44 7930 732 426 investor@ventanabiotech.com www.ventanabiotech.com